Market and media release

15th December 2020

AFT determination of Anita Baldauf independence

As announced on 4 November 2020, AFT Pharmaceuticals (NZX; AFT, ASX; AFP) appointed Anita Baldauf as a non-executive director. In accordance with NZX Listing Rule 2.6.1, the Board has determined that she is an Independent Director (within the meaning of the NZX Listing Rules).

For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer.

For more information:

Investors

Media

Malcolm Tubby

Richard Inder

CFO

The Project

AFT Pharmaceuticals

Tel: +64 21 645 643

Tel: +64 9488 0232

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand

Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

AFT Pharmaceuticals Limited published this content on 15 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 December 2020 01:52:03 UTC